Sun Pharma Q2 FY25 Results: Revenue grows 9%% YoY to ₹13,291 crore, Net Profit jumps 27.5% YoY to ₹3,040 crore
Sun Pharmaceutical Industries Limited reported robust Q2 FY25 financial results, reflecting strong year-over-year (YoY) growth in both revenue and net profit. The company continues to outperform market expectations with its expanding business operations across multiple geographies, particularly in the United States.
Key Financial Highlights:
-
- Q2 FY25 Revenue: ₹13,291.39 crore (₹132,913.9 million)
- Q2 FY24 Revenue: ₹12,192.41 crore (₹121,924.1 million)
This indicates a YoY revenue growth of approximately 9% (from ₹12,192.41 crore to ₹13,291.39 crore).
- Net Profit: The net profit for the quarter stood at ₹3,040.1 crore, up from ₹2,375.5 crore in the corresponding quarter last year, reflecting a 27.5% increase YoY.
On a quarter-on-quarter (QoQ) basis:
- Revenue increased from ₹12,524.5 crore in Q1 FY25 to ₹13,264.2 crore in Q2 FY25, reflecting a growth of 5.9%.
- Net Profit also improved, rising from ₹2,835.6 crore in the previous quarter to ₹3,040.1 crore this quarter, marking a 7.2% increase QoQ.
US Sales Performance:
- Sun Pharma US Formulation Sales: The company posted US formulation sales of $517 million, which represents a 20.3% YoY growth, indicating the company’s strong presence in the US market.
This growth is a big beat on YoY estimates and has exceeded market expectations, further strengthening Sun Pharma’s position as a leading global pharmaceutical player.
TOPICS:
Sun Pharma